COVID-19 Updates
-
BioUtah COVID-19 Life Sciences Survey
TIME SENSITIVE – PLEASE TAKE SURVEY Dear Members of Utah’s Life Sciences Community, BioUtah is taking a multi-pronged approach…
-
The Department of Health and Human Services on PREP
The Department of Health and Human Services issued a declaration on March 16 under the Public Readiness and…
-
H.R. 6201, the Families First Coronavirus Response Act Passed by the House 363-40 (3/14/2020)
Article courtesy of the National Association of Manufacturers Emergency Family and Medical Leave Expansion and Paid Sick Leave:…
-
Travel Considerations
Limit travel to only essential travel and have a clear definition of what constitutes “essential travel.” Monitor and…
-
Maintaining a Safe Workplace
Identify possible work-related exposure and health risks to your employees. Train and educate employees about COVID-19. Here are…
-
BioUtah Statement & Recommendations to Members on COVID-19
The advent and progression of the Novel Coronavirus, COVID-19, pandemic requires a proper and measured response from every…
-
Co-Diagnostics, Inc. Invited to Speak on Coronavirus at Molecular Med Tri-Con in San Francisco
March 03, 2020 06:30 AM Eastern Standard Time SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
